The Lead Episode 149: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing: Results from the ASCEND CSP Trial
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Welcome to the latest episode of late-breaker coverage from Heart Rhythm 2026 in Chicago, with host Deep Chandh Raja, MBBS, MD, PhD, FHRS and his guests Paul Chun Yih Lim, MBBS, FHRS and Abhishek Deshmukh, MD. This discussion reviews the late-breaking HRS 2026 trial Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing: Results from the ASCEND CSP Trial Arrhythmia, which evaluated a novel implantable cardioverter-defibrillator (ICD) lead designed specifically for left bundle branch area pacing (LBBAP). Faculty discuss the safety profile, implant success, pacing performance, and clinical implications of conduction system pacing using dedicated ICD technology, as well as how these findings may influence future device implantation strategies and physiologic pacing approaches in patients requiring defibrillator therapy.
  • Assess the safety and procedural performance outcomes associated with left bundle branch area pacing in patients requiring ICD therapy. 
  • Evaluate the potential role of conduction system pacing technologies in advancing physiologic pacing and device-based arrhythmia management.
  • Describe the design and intended clinical application of the novel ICD lead evaluated in the ASCEND CSP trial. 

Podcast Contributors

Deep Chandh Raja, MBBS, MD, PhD, FHRS
Paul Chun Yih Lim, MBBS, FHRS
Abhishek Deshmukh, MD
All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

D.C. Raja

Nothing to disclose.

A. Deshmukh

Honoraria/Speaking/Teaching/Consulting: GE Healthcare, Biotronik, Medtronic, Biosense Webster
Research: AltaThera Pharmaceuticals


P. Lim

Nothing to disclose.





Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.